Key Highlights

  • ClearOne (NASDAQ:CLRO) slid 11.68% to USD 4.99, with a Nasdaq delisting determination still under appeal.
  • Cellyan Biotechnology (NASDAQ:HKPD) climbed 9.29% to USD 2.00 and faces a January 11, 2027 bid price deadline.
  • Medicus Pharma (NASDAQ:MDCX) dropped 11.92% to USD 1.70 following a 50-to-1 consolidation.
  • Hain Celestial Group (NASDAQ:HAIN) rose 9.62% to USD 0.1470 in advance of November 9 earnings.
  • Clean Energy Technologies (NASDAQ:CETY) gained 13.64% to USD 1.00 after a convertible note disclosure.

ClearOne (NASDAQ:CLRO) (down USD 0.6599, 11.68%): A Delisting Ruling and a Merger Still Pending

ClearOne (NASDAQ:CLRO) was down 11.68% to USD 4.99 in pre-market trading on November 3, 2026, with an implied prior close of about USD 5.65 (calculated). No company announcement dated November 2 or November 3, 2026 was identified.

On October 8, 2026, Nasdaq staff decided to delist the shares for falling short of the USD 2.5 million stockholders' Equity requirement. The company said it would ask for a hearing, a step that pauses the action. As of October 30, the Cortigent merger with a Vivani Medical Subsidiary still awaited final regulatory approval, and closing depends on USD 10.0 million to USD 15.0 million in financing. Auditors have raised Going Concern doubt, and this Penny Stock faces heavy dilution risk.

Cellyan Biotechnology (NASDAQ:HKPD) (up USD 0.1700, 9.29%): A Gain Following a Reverse Split

Cellyan Biotechnology (NASDAQ:HKPD) rose 9.29% to USD 2.00 in pre-market trading on November 3, 2026. Its implied Monday close was about USD 1.83 (calculated). No company announcement dated October 30 to November 3, 2026 was identified, so the advance cannot be linked to a specific event.

A 1-for-20 reverse split became effective at market open on October 26, 2026, and Nasdaq set January 11, 2027 as the deadline to regain a closing bid of at least USD 1.00. The Hong Kong company distributes over-the-counter pharmaceutical products through cross-border subsidiaries and filed a shelf registration covering up to USD 200 million of securities, which could cause dilution if used.

Medicus Pharma (NASDAQ:MDCX) (down USD 0.2301, 11.92%): Swings Following a 50-to-1 Consolidation

Medicus Pharma (NASDAQ:MDCX) dropped 11.92% to USD 1.70 in pre-market trading on November 3, 2026, with an implied prior close of about USD 1.93 (calculated). No company press release or filing dated November 2 or November 3 was identified, and just about 1.9 million shares remain outstanding.

The consolidation became effective on October 12, 2026, and on October 23 Nasdaq confirmed minimum bid price compliance, although the company warned that continued compliance is not assured. A special meeting on December 2, 2026 will vote on a board-discretionary split of up to 50 post-split shares for each pre-split share, and the filing states this could largely undo the consolidation.

Hain Celestial Group (NASDAQ:HAIN) (up USD 0.0129, 9.62%): A Sub-Dollar Stock Before Results

Hain Celestial Group (NASDAQ:HAIN) climbed 9.62% to USD 0.1470 in pre-market trading on November 3, 2026. No announcement tied to the move was identified. On November 2 the company said it will release fiscal 2027 first quarter results before the market opens on November 9, with a call at 8:00 AM ET.

Nasdaq granted a second compliance period through March 22, 2027, and the stock must close at or above USD 1.00 for at least 10 consecutive Business days. The company said it intends to act, including a reverse split if needed. Total Debt stood at USD 558 million on June 30, 2026, and management is still seeking a lender extension of the December maturity.

Clean Energy Technologies (NASDAQ:CETY) (up USD 0.1200, 13.64%): A Rebound Alongside a Convertible Note

Clean Energy Technologies (NASDAQ:CETY) advanced 13.64% to USD 1.00 in pre-market trading on November 3, 2026. No filing or press release dated October 30 to November 3 was identified, so the cause remains unconfirmed.

A regulatory filing made public on October 21, 2026 disclosed an 8% convertible note of USD 500,000, convertible at 85% of the lowest traded price over the prior 10 trading days. On May 26, 2026 the company disclosed a Nasdaq notice over an unfiled Form 10-Q, and whether that filing has since been made was not confirmed. Notes priced at a discount can dilute holders once converted.

Where Things Stand

All five companies sit near a Nasdaq rule, whether the USD 1.00 bid price, the equity requirement or a filing deadline. Three rose and two fell, and in four of the five no catalyst was identified, which leaves thin trading and reverse split mechanics as possible drivers. Investors may track the ClearOne hearing outcome, the January 11, 2027 deadline for Cellyan Biotechnology, the December 2 meeting at Medicus Pharma, the November 9 results from Hain Celestial Group and any Clean Energy Technologies filing that addresses its notice.